Meet John Adlesich and some of his public health ideas on healthcare industry trends: New supply chain models for new care settings. Health care futurists believe that by 2040, most care will be delivered at home, in outpatient settings or virtually. Adapting to this new way of care — in terms of supplies and delivery methods — will require relationships with different types of vendors, such as retailers, contract employees and technology providers. This is an exciting but huge challenge: how to reimagine supply chains to deliver non-hospital-based care in a safe, cost-effective and high-quality way at scale. Smarter, faster, predictive information. Expect to see more automation software and artificial intelligence (AI) in health care supply chains. In addition to freeing personnel from repetitive tasks, these technologies can assist decision-makers in identifying trends and providing resources to workers. For example, predictive analytics focused on population health within an organization or system could alert managers to trending disease states and their associated supply needs. Supply chain managers could use AI tools to master the new transportation logistics of getting supplies to widely dispersed home care settings and so on.
John Adlesich about behavior therapy in 2021: VB is another Skinnerian theory that has evolved from ABA that helps children understand how and why we use language. The focus is on using language rather than on the rote learning of words. Use of language to achieve a desired goal is rewarded, even if the word and/or gesture produced is not exact. According to AutismSpeaks.org, VB therapy: Is better suited to encouraging desired behaviors/language rather than eliminating undesired ones Encourages understanding language and communication in order to meet the child’s needs and wants Can be implemented by trained psychologists, speech therapists, teachers, and parents Involves about 30 hours of scheduled therapy weekly but is likely to be more effective when reinforced in all the child’s learning and living domains Uses shaping as a technique, which means that close approximations of the desired behaviors are rewarded and, as those are mastered, the demand for accuracy increases.
John Adlesich about healthcare industry trends in 2021: The California versus Texas case came to the Supreme Court from a federal appeals court. If the Supreme Court affirms the appeals court ruling, the case will go back to the federal district court to decide on the issue of severability of the individual mandate from the rest of the ACA. At the November 2020 oral argument, it looked like the Supreme Court, including one or more of the new justices, was inclined to honor the doctrine of severability, making it less likely the ACA will face complete repeal. Additionally, the new slim Democratic majority in the Senate (thanks to the Georgia runoff) makes it likely that Congress would fix the constitutional problem by reinstating the mandate with a nominal penalty. John Adlesich currently works as administrator at Marquis Companies. His latest healthcare industry experience includes positions as executive director at Powerback Rehabilitation Lafayette (Genesis Healthcare) between Aug 2020 – Jan 2021, administrator at Mesa Vista of Boulder between Mar 2019 – Aug 2020, chief executive officer at Sedgwick County Memorial Hospital between Jul 2018 – Feb 2019, interim chief operating officer at Toiyabe Indian Health Project between Mar 2018 – Jun 2018.
John Adlesich believes that 2021 is a crossroads year for the healthcare industry. COVID-19 focused the nation’s attention on the risks associated with overreliance on overseas markets for critical supplies, drugs, and equipment. As an “easy” answer, some are now calling for manufacturers to produce a plurality of medical products domestically. While added domestic investments and expanded US manufacturing capacity are vital components of a holistic strategy for reliable supply, it will be important to strike a balanced approach—one that includes a domestic strategy, but at its core is about diversifying supply, including raw materials, pharmaceutical ingredients, and finished drugs. Achieving this vision requires a surgical approach, starting with identifying the products that are truly needed in an emergency to ensure there isn’t undue concentration in a single country or region. In our view, that means ensuring three or more global suppliers and at least one US-based source readily available to serve the American people. Assessing risk will require new transparency initiatives, requiring manufacturers of critical products to share vital information with government, including supply sources, centers of manufacturing, redundancy and contingency protocols, etc. And all this new information needs a technology backbone that helps government better track product availability, supply chain performance, and sources of supply to predict potential trouble spots in real time during another emergency.